The HmBMH@MSA‐2 nanosystem targeted tumor sites through CD44 receptors, underwent degradation under high GSH conditions in the TME, released MSA‐2 and Mn ions, and achieved targeted delivery of STING agonists and T1‐weighted magnetic resonance imaging (MRI). The gene discussed is STING1; the disease is neoplasm.